Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.88 |
| ▸ | CHAT | P28329 | 2/20 | 0.84 |
| ▸ | EP300 | Q09472 | 3/20 | 0.83 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.83 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857088 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| Ammonia Solution, Strong SCHEMBL60556 | 0.99 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL22556110 | 0.97 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29530678 | 0.97 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL59962 | 0.97 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL16585519 | 0.97 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL15299842 | 0.97 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19693052 | 0.97 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL284786 | 0.96 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL18918369 | 0.96 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305173-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | Lanzatech, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-116615549-A | Recombinant microorganism and use thereof | 朗泽科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| WO-2022192865-A9 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | LANZATECH, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| EP-3406724-B1 | RECOMBINANT MUTANT MICROORGANISMS HAVING ACRYLIC ACID PRODUCTIVITY AND METHOD FOR PRODUCING ACRYLIC ACID USING SAME | HANWHA CHEMICAL CORP (KR) | 2022-12-14 | — | — | EP | claimed |
| CN-108884465-B | Modified microorganism having acrylic acid-producing ability and method for producing acrylic acid using the same | 韩华石油化学株式会社 | 2022-11-15 | — | — | CN | claimed |
| WO-2022192865-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | LANZATECH, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220282289-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | UNITED STATES DEPARTMENT OF ENERGY | 2022-09-08 | — | — | US | claimed |
| US-10450593-B2 | Type II fatty acid synthesis enzymes in reverse β-oxidation | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-10-22 | — | — | US | claimed |
| US-9994881-B2 | Functionalized carboxylic acids and alcohols by reverse fatty acid oxidation in engineered microbes | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-06-12 | — | — | US | claimed |
| EP-3099763-A1 | TYPE II FATTY ACID SYSTHESIS ENZYMES IN REVERSE B-OXIDATION | William Marsh Rice University (US) | 2016-12-07 | — | — | EP | claimed |
| WO-2009089457-A1 | METHODS FOR PRODUCING 3-HYDROXYPROPIONIC ACID AND COMPOUNDS THEREOF | NOVOZYMES A/S (DK) | 2009-07-16 | — | — | WO | claimed |
| EP-1575881-B1 | ALANINE 2,3- AMINOMUTASE | NOVOZYMES AS (DK) | 2009-05-27 | — | — | EP | claimed |
| US-20080124785-A1 | ALANINE 2, 3-AMINOMUTASE | CARGILL, INCORPORATED | 2008-05-29 | — | — | US | claimed |
| US-7309597-B2 | To convert alpha-alanine to beta-alanine, beta-alanine, pantothenic acid, 3-hydroxypropionic acid | CARGILL, INCORPORATED (US) | 2007-12-18 | — | — | US | claimed |
| WO-2007047680-A2 | INCREASING THE ACTIVITY OF RADICAL S-ADENOSYL METHIONINE (SAM) ENZYMES | CARGILL, INCORPORATED (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1575881-A4 | ALANINE 2,3- AMINOMUTASE | CARGILL INC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050221466-A1 | Alanine 2,3,aminomutase | CARGILL, INCORPORATED | 2005-10-06 | — | — | US | claimed |
| EP-1575881-A2 | ALANINE 2,3- AMINOMUTASE | Cargill, Incorporated (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1575881-A3 | ALANINE 2,3- AMINOMUTASE | Cargill, Incorporated (US) | 2005-08-04 | — | — | EP | claimed |
| WO-2003062173-A2 | ALANINE 2,3- AMINOMUTASE | CARGILL, INCORPORATED (US) | 2003-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124785-A1 | ALANINE 2, 3-AMINOMUTASE | ALAD, AGXT, ABAT | NAA50 664/4885CHAT 1228/4885EP300 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.